HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SGI-1252

a small molecule inhibitor of JAK2.; structure in first source

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Polyamines: 3918
    - Diamines: 518
      - SGI-1252: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - SGI-1252: 2

Experts

1.	Deyhle, Michael R: 1 article (01/2018)
2.	Fuqua, Jordan D: 1 article (01/2018)
3.	Hancock, Chad: 1 article (01/2018)
4.	Hyldahl, Robert D: 1 article (01/2018)
5.	Parcell, Allen C: 1 article (01/2018)
6.	Parmley, Jacob: 1 article (01/2018)
7.	Skousen, Caitlin: 1 article (01/2018)
8.	Sorensen, Jacob R: 1 article (01/2018)
9.	Ahmed, Kausar Begam Riaz: 1 article (01/2011)
10.	Bearss, David J: 1 article (01/2011)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2011 - "Pharmacodynamic studies in a murine xenograft model demonstrated both anti-tumor activity and inhibition of signal transducers and activators of transcription 5 phosphorylation by SGI-1252, and the drug was active and well-tolerated whether delivered intraperitoneally or orally. "
2.	Primary Myelofibrosis (Myelosclerosis) 01/01/2011 - "Moreover, cell lines transfected with either wild-type JAK2 or JAK2(V617F) were equally susceptible to the antiproliferative effects of SGI-1252 and the antiproliferative activity of SGI-1252 toward ex vivo--expanded erythroid progenitors from patients with polycythemia vera and primary myelofibrosis appeared independent of the JAK2(V617F) allele burden. "
3.	Weight Gain 01/01/2018 - "SGI-1252 was well tolerated, as animals displayed similar weight gain over the 8-week treatment period. "
4.	Polycythemia Vera 01/01/2011 - "Moreover, cell lines transfected with either wild-type JAK2 or JAK2(V617F) were equally susceptible to the antiproliferative effects of SGI-1252 and the antiproliferative activity of SGI-1252 toward ex vivo--expanded erythroid progenitors from patients with polycythemia vera and primary myelofibrosis appeared independent of the JAK2(V617F) allele burden. "
5.	Fatigue 01/01/2018 - "Following treatment, fatigue in the gastrocnemius-soleus-plantaris complex was greater in the SGI-1252 mice during a 300 second tetanic contraction bout (p = 0.035), though both the rate of fatigue and maximal force production were similar. "

Related Drugs and Biologics

1.	trichostatin A (A 300)